Fig. 6

A Schematic timeline illustration of the in vivo immunisation and the serum anti-HBsAg IgG test. B Serum anti-HBsAg IgG concentrations after the prime immunisation with different formulations at the HBsAg concentration of 1 µg/leg (at the equivalent dose of 2 µg/mouse) on Day 14. C Serum anti-HBsAg IgG concentrations after the boost with different formulations at the HBsAg concentration of 1 µg/leg on Day 21. D Serum anti-HBsAg IgG concentrations after the second boost with different formulations at the HBsAg concentration of 1 µg/leg on Day 35 or E on Day 42, respectively. F The serum anti-HBsAg IgG1 concentrations, G anti-HBsAg IgG2a concentrations and (H) the anti-HBsAg IgG2a/IgG1 concentration ratios after the second boost with different formulations at the HBsAg concentration of 1 µg/leg on Day 42, respectively. One-way ANOVA was used for statistical analyse